Tagged with Researc

Spain Stephen Matlin, CEO of Life Length, highlights the evolution of the company over recent years, especially the establishment of their own laboratories which have allowed them to conduct clinical studies for diagnostic and prognostic tests in cancer. Furthermore, he points out the need to better value preventative medicine and how…

China Dr Dan Zhang, CEO of Fountain Medical Development (FMD), details the transformation China’s recent membership at the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) will bring to the drug development and clinical research landscape in China, the pressures and opportunities local companies…

China Dr Wang Yinxiang, chairman; and Dr Hu Shaojing, President (R&D); of Jacobio Pharmaceutical; share the exciting story behind Jacobio’s establishment in 2015, their ambition to become a global biopharma player with the plan of launching at least one IND every year and to open a research lab in Boston; and…

France Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to the unprecedented wave of innovation that is revolutionizing the health industry.   In terms of research, we have invested EUR…

UK An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research.  According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people donated to medical research charities which funded £1.6bn in research and accounted for 47% of all publicly-funded medical research in…

Korea Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals how Daiichi Sankyo Korea plans to embrace the company’s global strategy of expanding into the new area of oncology.  …

Spain Jesús Fernández-Pacheco Mena, country manager of hmR Spain, a health market research specialist, highlights the innovative “sell out” model of obtaining market data and the strategy in place to change the industry´s mindset to utilize this information. Furthermore, he highlights the services they provide and how this will evolve in…

USA PJ Brooks PhD, program director in the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) in the USA, highlights the importance of going beyond one disease at a time in clinical trials, some of the roadblocks that still remain…

Spain Joan Puig de Dou, CEO of Kymos Pharma, a Spanish analytical CRO, shares his insights in the changing dynamics of the industry and explains how remaining independent in the face of industry consolidation is a strategic priority to leverage both quality and specialization for the company’s clients.   When[biosimilars] come…

France Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core Europe, a collaborative platform of Europe’s seven leading cancer institutes.   Our system brings between 3500 and 4000 patients into…

Korea The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced technologies to drive the nation’s economic growth as well as better care for patients at home and abroad.   For…

Spain Luis Serrano, president of the Centre for Genomic Regulation (CRG) in Spain, gives an update on the Centre’s recent history and outlines the need for greater understanding of science and research within the Spanish political class.   When we enter discussions with the different political parties, I feel things are…